Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 3, 1996, Pages 359-366

  Hartmann, M ^a   Theiss U ^b   Huber, R ^a   Luhmann R ^a   Bliesath, H ^a   Wurst, W ^a   Lucker P W ^b  

^a ALTANA PHARMA AG   (Germany)

^b Prof Dr Lucker GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; BENZIMIDAZOLES; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIET; ENZYME INHIBITORS; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HALF-LIFE; HUMANS; MALE; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 0029992205     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-0673.1996.00359.x     Document Type: Article

References (23)

1. Kromer W, Postius S, Riedel R, et al. BY1023/SK&F 96022 INN Pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 1990; 254: 129-55.
2. Tucker G. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 53-8.
3. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 1994; 32: 385-99.
4. +-ATPase inhibitor BY1023/ SK&F96022 - inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990; 4: 239-45.
5. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 1990; 28: 443-7.
6. Simon B, Müller P, Marinis E, et al. Effect of repeated oral administration of BY1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990; 4: 373-9.
7. Müller P, Simon B, Khalil H, et al. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992; 30: 771-75.
8. Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 47-52.
9. Schepp W, Rehner M, Witzel L. A review of treatment of duodenal and gastric ulcers, pantoprazole vs. omeprazole. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 53-8.
10. Judmaier G, Koelz HR. Pantoprazole-Duodenal Ulcer Study Group. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 1994; 8: 81-6.
11. Brunner G, Harke U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 59-64.
12. +-ATPase inhibitor BY1023/SK&F96022 and its sulfone metabolite in serum or plasma by direct injection and fully automated precolumn sample cleanup. J Chromatogr 1990; 529: 389-401.
13. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28: 577-84.
14. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz HU. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992; 30 (Suppl. 1): S31-5.
15. Koop H, Kuly S, Schneider A, Rose K. Comparison of 24-h intragastric pH and 24-h gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole. Gut 1994; 35 (Suppl. 4): A79.
16. Cederberg C, Röhss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 18: 179-84.
17. Dammann HG, von zur Mühlen A, Balks HJ, et al. The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993; 7: 191-6.
18. Sharma BK, Walt RP, Pounder RE, et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
19. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in man. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 39-46.
20. Cederberg C, Thomson ABR, Mahachai V, et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 913-8.
21. Verdú EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
22. Ching MS, Mihaly GW, Angus PW, et al. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Pharmacol 1991; 31: 166-70.
23. Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45-52.